142 related articles for article (PubMed ID: 35029519)
1. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study.
Rizzo A; Santoni M; Mollica V; Logullo F; Rosellini M; Marchetti A; Faloppi L; Battelli N; Massari F
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1455-1466. PubMed ID: 35029519
[TBL] [Abstract][Full Text] [Related]
2. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Santoni M; Rizzo A; Kucharz J; Mollica V; Rosellini M; Marchetti A; Tassinari E; Monteiro FSM; Soares A; Molina-Cerrillo J; Grande E; Battelli N; Massari F
Cancer Immunol Immunother; 2023 Jun; 72(6):1365-1379. PubMed ID: 36633661
[TBL] [Abstract][Full Text] [Related]
3. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.
Rizzo A; Mollica V; Tateo V; Tassinari E; Marchetti A; Rosellini M; De Luca R; Santoni M; Massari F
Cancer Immunol Immunother; 2023 Jun; 72(6):1381-1394. PubMed ID: 36695827
[TBL] [Abstract][Full Text] [Related]
4. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.
Santoni M; Rizzo A; Mollica V; Matrana MR; Rosellini M; Faloppi L; Marchetti A; Battelli N; Massari F
Crit Rev Oncol Hematol; 2022 Feb; 170():103596. PubMed ID: 35031442
[TBL] [Abstract][Full Text] [Related]
5. Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis.
Abdel-Rahman O
Immunotherapy; 2019 Apr; 11(6):543-554. PubMed ID: 31135244
[No Abstract] [Full Text] [Related]
6. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y
Front Immunol; 2020; 11():595655. PubMed ID: 33391266
[TBL] [Abstract][Full Text] [Related]
7. Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.
Trontzas IP; Rapti VE; Syrigos NK; Kounadis G; Perlepe N; Kotteas EA; Bamias G
Immunotherapy; 2021 Sep; 13(13):1085-1092. PubMed ID: 34247513
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Peng L; Bu Z; Ye X; Zhou Y; Zhao Q
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26537178
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity of antibodies in cancer therapy: A review.
Horta E; Bongiorno C; Ezzeddine M; Neil EC
Clin Neurol Neurosurg; 2020 Jan; 188():105566. PubMed ID: 31731087
[TBL] [Abstract][Full Text] [Related]
10. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Xu M; Nie Y; Yang Y; Lu YT; Su Q
Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716
[TBL] [Abstract][Full Text] [Related]
11. Immune mediated neuropathy following checkpoint immunotherapy.
Gu Y; Menzies AM; Long GV; Fernando SL; Herkes G
J Clin Neurosci; 2017 Nov; 45():14-17. PubMed ID: 28765062
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
[TBL] [Abstract][Full Text] [Related]
13. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
Roy B; Das A; Ashish K; Bandyopadhyay D; Maiti A; Chakraborty S; Stone ME; Philpotts LL; Nowak RJ; Patwa HS
Neurology; 2019 Jul; 93(2):e143-e148. PubMed ID: 31167931
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy.
Zhao B; Zhao H; Zhao J
Crit Rev Oncol Hematol; 2018 Aug; 128():110-117. PubMed ID: 29958626
[TBL] [Abstract][Full Text] [Related]
15. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors.
Mohrmann C; Armer J; Hayashi RJ
J Pediatr Oncol Nurs; 2017; 34(2):106-114. PubMed ID: 27251891
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
18. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.
Hershman DL; Till C; Wright JD; Awad D; Ramsey SD; Barlow WE; Minasian LM; Unger J
J Clin Oncol; 2016 Sep; 34(25):3014-22. PubMed ID: 27325863
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer: Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes.
Kandula T; Farrar MA; Cohn RJ; Mizrahi D; Carey K; Johnston K; Kiernan MC; Krishnan AV; Park SB
JAMA Neurol; 2018 Aug; 75(8):980-988. PubMed ID: 29799906
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
